Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III pivotal, multicenter, double-blind, randomized, placebo-controlled study of milnacipran for the treatment of fibromyalgia

Trial Profile

A phase III pivotal, multicenter, double-blind, randomized, placebo-controlled study of milnacipran for the treatment of fibromyalgia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Fibromyalgia; Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 24 Oct 2020 Results of two large analgesic clinical trials (NCT00098124 and NCT00436033) for the treatment of fibromyalgia to evaluate the utility of different pain indices for detecting intervention effects, published in the Journal of Pain
    • 20 May 2009 Additional reference added (1132643) relating to published results from 162nd Annual Meeting of the American Psychiatric Association.
    • 07 May 2009 Results presented at the 28th Annual Scientific Meeting of the American Pain Society (APS 2009).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top